In part two of an exclusive interview, Novo Nordisk’s Maziar Mike Doustdar expands on the potential of emerging markets to foster innovation, managing risk, local partnerships, and the company's unwavering commitment to fighting diabetes.
To what extent can immature markets become sources of innovation in healthcare technologies? Does limited infrastructure not offer new opportunities to invest and test out alternative approaches?
The four 'must win battlegrounds’ are about ensuring better treatment for patients through raising greater awareness [of diabetes], attaining better access to care, delivering launch excellence for innovative products and sourcing the very best human capital for taking us forwards
